Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis

Recruiting N/A Interventional Study
Pancreatitis, Acute
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Efferon JSC · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in combination with hemofiltration (HF) / hemodiafiltration (HDF), with the goal of reducing the severity of organ dysfunction (measured by SOFA score) in patients with acute pancreatitis. Participants will be assigned to two groups for compariso…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * ≤ 5 days from the onset of acute pancreatitis * Acute pancreatitis of moderate or severe according to the Atlanta classification (2012) * Acute pancreatitis confirmed by tomography. Modified CTSI Pancreatitis Severity Index Score ≥ 4 points * APACHE II \> 8 * ≥ 2 points on the…
Contacts

Alexandr Shelehov-Kravchenko, PhD, MD

+79636564765

alexandr.shelehov@gmail.com

CONTACT